Leadership, governance, and the shared vision behind PhysioVerse

How We Evolved

A shared vision shaped by leaders across sectors

Microphysiological systems (MPS), including organoids and body-on-chip platforms, are emerging technologies that model human biology with unprecedented physiological relevance, enabling new approaches to studying safety, toxicity, and performance across multiple industries. These systems have the potential to improve predictive accuracy, reduce reliance on animal testing, and accelerate innovation in areas ranging from biotechnology to chemicals and materials. However, the lack of standardized data structures, validation frameworks, and interoperable datasets across organizations and regulatory agencies limits their broader adoption and impact. This fragmentation results in duplicated effort, high costs, and inconsistent evaluation pathways across sectors.

Leaders from across industry, government, academia, and other nonprofit organizations and foundations have been converging annually for over 10 years with the goal of advancing biomanufacturing standards for cells, biomaterials, organoids, tissues, and body-on-chip (BOC) platforms.

The most recent gathering in December 2025 in Charlotte, NC, with representation from multiple government agencies, including ARPA-H, BARDA, DHA, DOW, FDA, GAO, ISSNL, NASA, NSF, and others, resulted in the generation of four roadmaps that provide a path forward and highlight critical gaps in the field of microphysiological systems. PhysioVerse addresses these gaps by establishing an open-source cyberinfrastructure that enables reproducible, regulator-aligned validation and interoperability of MPS-generated data, supporting pre-competitive collaboration and advancing data harmonization and validation science across multiple ecosystems.